Pharmacometrics

Pharmacometrics encompasses quantitative modelling and simulation approaches that integrate pharmacokinetics, pharmacodynamics, disease progression, and variability sources to support drug development and clinical decision-making. This discipline applies mathematical and statistical models to describe how drugs behave in populations, predict therapeutic responses, optimise dosing regimens, and evaluate uncertainty.

The biopharmaceutical industry increasingly relies on pharmacometrics for model-informed drug development, using population PK models to understand variability across age, weight, renal function, or comorbidities, exposure-response models linking drug concentrations to efficacy and safety outcomes, and simulation tools predicting outcomes under different dosing strategies. Regulatory agencies encourage pharmacometric submissions supporting dose selection, paediatric extrapolation, and trial design optimisation. Pharmacometrics supports precision dosing for narrow therapeutic index drugs, optimises combination therapy regimens, and informs label recommendations. Challenges include model assumptions, data quality, and ensuring clinical interpretability, requiring collaboration between clinicians, statisticians, and modellers. As computational power expands and real-world evidence becomes more available, pharmacometrics continues evolving as an essential quantitative framework accelerating development efficiency and supporting safer, more effective therapeutic use.